Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential administration, dosing and therapeutic benefit of Clolar in various cancer indications; the expected results of the data generated from the Clolar clinical trials; and the requirements and plans for regulatory filings and approvals for Clolar in additional indications. These risks and uncertainties include, among others, the timing of discussions with the FDA regarding clinical studies and approval of Clolar in additional indications; the timing and content of decisions by the FDA related to clinical trials and approval of Clolar in additional indications; the actual efficacy and safety of Clolar for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... the development and commercialization of innovative therapies for the ... PDUFA date for Zalviso remains July 27, 2014.  ... online stating the Food and Drug Administration (FDA) had ... been no notification to the company from the FDA ...
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... -- Amgen (NASDAQ: AMGN ) today announced that ... July 29, 2014, after the close of the U.S. financial ... with the investment community at 2 p.m. PT. Participating in ... , chairman and chief executive officer, and other members of ... conference call will be simultaneously broadcast over the Internet and ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/26/2014)... According to the Banish My Bumps ... comprehensive guide that covers detailed instructions on how to ... need of any medication. , Vkool reveals in ... safe remedies for relieving symptoms of keratosis pilaris quickly. ...     How to treat children's keratosis pilaris , ...
(Date:7/25/2014)... Staffordshire, UK (PRWEB) July 26, 2014 ... a variety of dental services including general dentistry, clear ... practice opening in September this year in Derby. The ... is at the HollyBrook Medical Centre in Littleover, Derby. ... the new practice. , The new dental practice, which ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... July 25, 2014 As reported by the ... War On Heroin (7/20), police in Salem, MA as ... down on the recent heroin epidemic that has taken many ... on one heroin-related overdose case in which police were able ... victim's cell phone. By pretending to be the victim and ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Seniors are more easily distracted ... new study finds. "Almost any type of memory ... age of 25 on," study co-author Randi Martin, professor ... news release. However, Martin said, this study shows ... in older adults compared with younger adults. The ...
Breaking Medicine News(10 mins):Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2
... made from some of the same parts used in ... way to measure the growth and drug susceptibility of ... The new biosensor promises to speed treatment of ... Smalley Distinguished University Professor of Chemistry, Physics and Applied ...
... Thea Friedman, M.D., associate scientist and director of ... at Hackensack University Medical Center was recently awarded a ... RO1 research grant to improve allogeneic blood and marrow ... $2 million in funding over the next five years. ...
... a successful Phase 1 study for safety, researchers at ... today announced the beginning of a Phase 2 clinical ... they developed to prevent hepatitis C virus (HCV) ... The first patients were enrolled in the study in ...
... - A recent study by Merikangas and colleagues published ... of the American Academy of Child and Adolescent Psychiatry ... are affected with severely impairing mental disorders ever receive ... that approximately one third of adolescents with any mental ...
... researchers have used a type of brain scanning, known as ... in blood flow in the brain and to correlate this ... data, which could improve is reported in the International ... have known since the 1890s that changes in blood flow ...
... risk factors for breast cancer are well studied and documented. ... period, late onset of menopause and a family history of ... However, neither an individual woman nor medicine can influence ... menopause starts - these are risk factors on which we ...
Cached Medicine News:Health News:See how they grow: Monitoring single bacteria without a microscope 2Health News:See how they grow: Monitoring single bacteria without a microscope 3Health News:Oncology basic research director at John Theurer Cancer Center continues transplantation research 2Health News:First liver transplant patients receive experimental drug to prevent hepatitis C infection 2Health News:First liver transplant patients receive experimental drug to prevent hepatitis C infection 3Health News:Adolescents with severe mental disorders have never received treatment 2Health News:Functional boost for magnetic resonance imaging 2Health News:Scientists identify avoidable breast cancer risk factors 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: